Drug intelligence / Profile preview

KI-1127

Development stage: Preclinical
Lead developer: Kuhnil Pharmaceutical
Modality: Small Molecules

Overview

KI-1127 is an investigational small molecule drug candidate developed by Kuhnil Pharmaceuticals for the treatment of hyperlipidemia. It is currently in the preclinical stage of development. The drug is part of Kuhnil's metabolic disease pipeline, which focuses on addressing lipid disorders and associated conditions. While the specific molecular target and mechanism of action for KI-1127 have not been publicly disclosed, it represents part of the company's effort to expand its portfolio of cardiovascular and metabolic therapies.

Beyond the preview

Go deeper on KI-1127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KI-1127.

Explore the full profile